Michael J. McNamara

Michael J. McNamara

Auto-generated profile, based on publicly available information

Michael J. McNamara

Taussig Cancer Institute, Cleveland Clinic, Cleveland, 44195, OH, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2018 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
LSLillian Sun
Lillian Sun
Pauline FunchainPauline Funchain
Pauline Funchain
JSJung Min Song
Jung Min Song
PRPatricia Rayman
Patricia Rayman
CTCharles Tannenbaum
Charles Tannenbaum
BGBrian Gastman
Brian Gastman
Background Talimogene Laherparepvec (T-VEC) is an oncolytic virus approved as an intratumoral therapy for treating unresectable stage IIIB-IV metastatic melanoma. The mechanisms of action for T-VEC and checkpoint inhibitor are highly complementary. Recent studies have shown that combining checkpoint inhibitor therapy with T-VEC injection can lead to improved response rates for stage IIIB-IV melanoma patients. Methods We reviewed 10 consecutive cases of stage IIIC to stage IVM1b melanoma patients that received T-VEC plus checkpoint inhibitor(s) therapy (pembrolizumab, ipilimumab/nivolumab, or nivolumab) treated between June 2016 and August 2017 at the Cleveland Clinic with a median follow-up of 7 months (range: 4 to 13 months). Responses of injected (on-target) and uninjected (off-target) lesions were evaluated according to RECIST 2.0. Results The overall response rate for on-target lesions was 90%, with 6 patients experiencing a complete response in injected lesions. Two patients had off-target lesions, which were completely resolved after treatment. Blood samples were tested for 3 complete responders and 2 partial responders. CD4:CD8 ratio and frequencies of circulating PD1+ CD4 and CD8 T cells were elevated in complete responders but not partial responders. One patient died due to causes unrelated to melanoma and one patient died of progression of the disease. Conclusion Our data suggest that combining checkpoint inhibitor(s) with T-VEC injection may provide a synergistic efficacy for patients with unresectable melanoma. We observed a better overall response rate and complete response rate compared to published studies on similar therapeutic regimens.

29 April 2012 in Current Oncology Reports
Verified
Journal Article
Closed access
PDF file
MMMichael J. McNamara
Michael J. McNamara
DADavid J. Adelstein
David J. Adelstein

1 October 2014 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
MMMichael J. McNamara
Michael J. McNamara
DADavid J. Adelstein
David J. Adelstein
JBJoanna W. Bodmann
Joanna W. Bodmann
JGJohn F. Greskovich
John F. Greskovich
DIDenise I. Ives
Denise I. Ives
LRLisa A. Rybicki
Lisa A. Rybicki
Adenocarcinoma of the distal esophagus and gastroesophageal junction (GEJ) is characterized by late presentation, early dissemination, and aggressive clinical behavior. Solid food dysphagia, the most common presenting symptom, is usually not experienced until the disease is locally advanced, having breached the esophageal wall or metastasized to regional lymph nodes. The prognosis for patients with locoregionally advanced disease is poor when patients are treated with surgery alone. Both local failure and distant failure are common, occurring in approximately 20% to 40% and 50% of patients, respectively.1 x 1 Urba, SG, Orringer, MB, Turrisi, A, Iannettoni, M, Forastiere, A, and Strawderman, M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001; 19: 305–313 PubMed | Google Scholar See all References ,2 x 2 Ychou, M, Boige, V, Pignon, JP et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011; 29: 1715–1721 Crossref | PubMed | Scopus (732) | Google Scholar See all References The reported 5-year survivals for patients with locoregionally advanced (LRA) disease treated with surgery alone range between 5% and 30%.3 x 3 Cunningham, D, Allum, WH, Stenning, SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355: 11–20 Crossref | PubMed | Scopus (2993) | Google Scholar See all References , 4 x 4 Kelsen, DP, Ginsberg, R, Pajak, TF et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998; 339: 1979–1984 Crossref | PubMed | Scopus (1056) | Google Scholar See all References , 5 x 5 van Hagen, P, Hulshof, MC, van Lanschot, JJ..., and CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366: 2074–2084 Crossref | PubMed | Scopus (1712) | Google Scholar See all References , 6 x 6 Walsh, TN, Noonan, N, Hollywood, D, Kelly, A, Keeling, N, and Hennessy, TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996; 335: 462–467 Crossref | PubMed | Scopus (1607) | Google Scholar See all References

1 April 2016
Verified
Journal Article
Open access
PDF file
MMMichael J. McNamara
Michael J. McNamara
LRLisa A. Rybicki
Lisa A. Rybicki
DSDavendra Sohal
Davendra Sohal
DADaniela S. Allende
Daniela S. Allende
GVGregory M. M. Videtic
Gregory M. M. Videtic
DADavid J. Adelstein
David J. Adelstein
The relationship between pathologic nodal disease and residual tumor viability after induction chemotherapy in patients with locally advanced esophageal adenocarcinoma receiving a tri-modality regimen

12 October 2016 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
PDF file
MMMichael J. McNamara
Michael J. McNamara
DADavid J. Adelstein
David J. Adelstein
DADaniela S. Allende
Daniela S. Allende
JBJoanna W. Bodmann
Joanna W. Bodmann
DIDenise I. Ives
Denise I. Ives
LRLisa A. Rybicki
Lisa A. Rybicki